|
[Logo - CDER] CHEMISTRY REVIEW TEMPLATE
[Logo - CDER] |
Chemistry Assessment Section
|
NDA |
20-358 |
Wellbutrin SRŪ Tablets |
18. STATUS
ONDC:
|
CONSULTS/CMC RELATED
REVIEWS |
RECOMMENDATION |
DATE |
REVIEWER |
|
Biometrics |
N/A |
N/A |
N/A |
|
EES |
Acceptable |
4/21/03 |
Office
of Compliance |
|
Pharm/Tox |
N/A |
N/A |
N/A |
|
Biopharm |
Acceptable
pending outcome of DSI inspection |
5/12/03 |
Sally
Yasuda |
|
Methods
Validation |
Pending |
Pending |
Sherita
McLamore, Ph.D. |
|
DMETS |
Acceptable |
5/9/03 |
Jennifer
Fan, Pharm.D. |
|
EA |
Categorical
Exclusion Granted |
5/25/05
(date impossible s/b 5/25/03?) |
Sherita
McLamore, Ph.D. |
|
Microbiology |
N/A |
N/A |
N/A |
The Chemistry Review for NDA
21-515
The Executive Summary
I.
Recommendations
A.
Recommendation and Conclusion on Approvability
The Chemistry, Manufacturing, and Controls (CMC)
section of NDA 21-515 is complete and is recommended for approval.
Methods validation will be submitted.
B.
Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements,
and/or Risk Management Steps, if Approvable
N/A
II.
Summary
of Chemistry Assessments
A.
Description of the Drug Product(s) and Drug
Substance(s)
Page 7 of 16
Back a Page
Next Page
Back to Wellbutrin XL NDA Index Page
Back to Main Index Page